Affordable Access

Publisher Website

Non-alcoholic fatty liver disease, liver fibrosis score and cognitive function in middle-aged adults: The Framingham Study.

  • Weinstein, Galit1
  • Davis-Plourde, Kendra2, 3
  • Himali, Jayandra J2, 3, 4
  • Zelber-Sagi, Shira1, 5
  • Beiser, Alexa S2, 3, 4
  • Seshadri, Sudha3, 4, 6
  • 1 School of Public Health, University of Haifa, Haifa, Israel. , (Israel)
  • 2 Department of Biostatistics, Boston University School of Public Health, Boston, Massachusetts.
  • 3 The Framingham Study, Framingham, Massachusetts.
  • 4 Department of Neurology, Boston University School of Medicine, Boston, Massachusetts.
  • 5 Liver Unit, Department of Gastroenterology, Tel-Aviv Medical Center, Tel-Aviv, Israel. , (Israel)
  • 6 Glenn Biggs Institute for Alzheimer's and Neurodegenerative Diseases, University of Texas Health Sciences Center, San Antonio, Texas.
Published Article
Liver international : official journal of the International Association for the Study of the Liver
Publication Date
Sep 01, 2019
DOI: 10.1111/liv.14161
PMID: 31155826


Non-alcoholic fatty liver disease (NAFLD) is common and has been recently related to brain health. We aimed to assess the relationships of NAFLD and its severity, using the NAFLD fibrosis score (NFS), with cognitive performance. Framingham study Offspring and 3rd generation participants were included if they attended exams 9 (2002-2008) and 2 (2008-2011), respectively, were free of dementia and stroke, and did not have excessive alcohol intake. Between 2008 and 2011, participants underwent Multi-detector computed tomography scans of the abdomen to determine NAFLD diagnosis and the NFS was used to categorize the severity of fibrosis. Cross-sectional relationships of NAFLD and the NFS with cognitive testing of memory, abstract reasoning, visual perception, attention and executive function were assessed, while adjusting for multiple cardiometabolic variables including visceral adipose tissue, diabetes and insulin resistance. Of the 1287 participants (mean age = 61±12 years, 48% men), 378 (29%) had NAFLD. The presence of NAFLD was not associated with cognitive function. However, among those with NAFLD (mean age = 61±12 years; 58% men), high compared to low risk of advanced fibrosis was associated with poorer performance on similarities (β = -2.22 ± 0.83; P = 0.009) and trail-making B minus A (β = -0.11 ± 0.05; P = 0.028), independently of potential confounders. Participants with high risk of advanced fibrosis may have poorer cognitive function compared to those with low risk, particularly in executive function and abstract reasoning. Future findings are necessary to evaluate the value of the NFS as a biomarker that predicts cognitive impairment and dementia and to explore the role of hepatic fibrosis in brain health. © 2019 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Report this publication


Seen <100 times